XNAS
PEPG
Market cap49mUSD
Jun 10, Last price
1.50USD
1D
-1.32%
1Q
-39.27%
IPO
-87.39%
Name
PepGen Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.12%
Rev. gr., 5y
%
Revenues
0k
Net income
-90m
L+14.44%
CFO
-82m
L+19.38%
Profile
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 97,739 | 85,950 | 68,794 | |||
Unusual Expense (Income) | ||||||
NOPBT | (97,739) | (85,950) | (68,794) | |||
NOPBT Margin | ||||||
Operating Taxes | 617 | 73 | 3,706 | |||
Tax Rate | ||||||
NOPAT | (98,356) | (86,023) | (72,500) | |||
Net income | (89,981) 14.44% | (78,626) 13.78% | (69,104) 153.30% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 86,778 | (189) | 112,193 | |||
BB yield | -72.50% | 0.12% | -35.39% | |||
| Debt | ||||||
Debt current | 3,094 | 6,008 | 5,553 | |||
Long-term debt | 34,228 | 37,204 | 43,515 | |||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (82,869) | (67,195) | (134,157) | |||
| Cash flow | ||||||
Cash from operating activities | (82,372) | (68,997) | (59,265) | |||
CAPEX | (497) | (2,599) | (3,755) | |||
Cash from investing activities | (37,668) | (32,003) | (3,755) | |||
Cash from financing activities | 88,749 | (189) | 112 | |||
FCF | (95,120) | (84,523) | (101,748) | |||
| Balance | ||||||
Cash | 120,191 | 110,407 | 181,752 | |||
Long term investments | 1,473 | |||||
Excess cash | 120,191 | 110,407 | 183,225 | |||
Stockholders' equity | (271,437) | (181,446) | 114,505 | |||
Invested Capital | 408,718 | 312,975 | 86,412 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 31,583 | 23,796 | 23,713 | |||
Price | 3.79 -44.26% | 6.80 -49.14% | 13.37 | |||
Market cap | 119,700 -26.03% | 161,813 -48.96% | 317,045 | |||
EV | 36,831 | 94,618 | 400,328 | |||
EBITDA | (92,486) | (84,766) | (68,301) | |||
EV/EBITDA | ||||||
Interest | 3,396 | |||||
Interest/NOPBT | ||||||